Clinical trials: Attention Deficit Disorders With Hyperactivity
- Condition Attention Deficit Disorders With Hyperactivity
- Funder type Industry (pharma, biotech, devices)
Attention Deficit Hyperactivity Disorder
Comparison of Atomoxetine Versus Placebo in Children With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a two-arm, parallel, randomized, double-blind, placebo-controlled Phase 4 multicenter trial to compare the whole day efficacy of atomoxetine versus placebo in children aged 6 through 12 years with…
- Trial name
- NCT00546910
- Testing
- Atomoxetine
- Where
- 16 sites in Germany
- Volunteers
- 125 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Hyperactivity Disorder
Atomoxetine to Treat Asian Adult Patients With Attention-Deficit/Hyperactivity Disorder
The purpose of this study is to assess the efficacy, the quality of life, and the safety of multiple dosing atomoxetine in Asian adult subjects with attention deficit/hyperactivity disorder (ADHD).
- Trial name
- NCT00962104
- Testing
- Atomoxetine
- Where
- 24 sites in Japan, South Korea and 1 more
- Volunteers
- 391 people
- Sponsor
- Eli Lilly and Company
Attention Deficit Disorder With Hyperactivity
Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy
This study will assess the safety and tolerability of MTS while attempting to establish the appropriate starting dose for subjects previously on an existing long-acting methylphenidate product.
- Trial name
- NCT00151983
- Testing
- Methylphenidate Transdermal System
- Where
- 18 sites in United States
- Volunteers
- 175 people
- Sponsor
- Noven Therapeutics
Attention Deficit Hyperactivity Disorder
Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder
This study will be a randomized, double-blind, placebo-controlled crossover study to assess the effects of GTS21 (25 mg three times a day (tid), 75 mg tid, 150 mg tid) compared to placebo in non-smoking adults aged 18-55 with a…
- Trial name
- NCT00419445
- Where
- 2 sites in United States
- Volunteers
- 37 people
- Sponsor
- CoMentis
Attention Deficit Hyperactivity Disorder
A Randomized, Double-Blind Comparison of Placebo and Atomoxetine Hydrochloride Given Once a Day in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)
This is a parallel design, double-blind, placebo-controlled, multi-center, 38-week treatment trial of atomoxetine in adults with attention deficit hyperactivity disorder (ADHD) who are currently living in a family situation with…
- Trial name
- NCT00190775
- Testing
- Atomoxetine Hydrochloride
- Where
- 21 sites in United States, Puerto Rico
- Volunteers
- 502 people
- Sponsor
- Eli Lilly and Company
Insomnia, Attention Deficit Hyperactivity Disorder
Long Term Safety Study of Study Drug (Eszopiclone) in Children and Adolescents With ADHD -Associated Insomnia
A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.
- Trial name
- NCT00857220
- Testing
- eszopiclone
- Where
- 89 sites in United States
- Volunteers
- 304 people
- Sponsor
- Sumitomo Pharma America, Inc.
Attention-Deficit/Hyperactivity Disorder (ADHD)
Evaluation of Immediate-Release Viloxazine in Adults With ADHD
This will be a randomized, double-blind, placebo-controlled, parallel group, safety and tolerability study in adults with ADHD. The target subjects are healthy male or female adults aged 18 to 64 years, inclusive, with a…
- Trial name
- NCT01107496
- Testing
- IR Viloxazine
- Where
- 4 sites in United States
- Volunteers
- 52 people
- Sponsor
- Supernus Pharmaceuticals, Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Pharmacokinetic Study in Children and Adolescents Aged 6 to 17 Years Who Have Been Diagnosed With ADHD
To provide additional, required information on the pharmacokinetic profile of SHP465 in the targeted population (children and adolescents aged 6-17 years of age with ADHD).
- Trial name
- NCT02578030
- Testing
- SHP465 12.5mg, SHP465 25mg
- Where
- 3 sites in United States
- Volunteers
- 27 people
- Sponsor
- Shire
Inflammatory Bowel Diseases, Depressive Episode
Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health
This study is a large population-based analysis in the United Kingdom (UK) using routine primary care data to investigate the impacts on quality-of-life outcomes and use of healthcare services in people aged 5 - 25 years…
- Conditions
- Inflammatory Bowel Diseases, Depressive Episode, Recurrent Depressive Disorder, Anxiety Disorder
- Trial name
- NCT05206734
- Testing
- No specific intervention
- Where
- United Kingdom
- Volunteers
- 19,469 people, healthy volunteers welcome
- Sponsor
- Momentum Data
Attention-Deficit/Hyperactivity Disorder
Pharmacokinetic Study of Methylphenidate HCl Extended-Release Capsules in Children 4 to Under 6 Years of Age With ADHD
To assess the pharmacokinetics of a single dose of Aptensio XR® (methylphenidate hydrochloride extended-release) capsules under fed conditions in male or female children 4 to under 6 years of age with ADHD.
- Trial name
- PK003 (NCT02470234)
- Testing
- Methylphenidate HCl ER Capsules, 10 mg, Methylphenidate HCl ER Capsules, 15 mg, Methylphenidate HCl ER Capsules, 20 mg
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Rhodes Pharmaceuticals, L.P.
Attention Deficit Hyperactivity Disorder (ADHD)
Effects of Probiotics on the Gut-brain Axis in Children
The effect of probiotics on the gut-brain axis in children with attention deficit hyperactivity disorder will be studied.
- Trial name
- NCT07459699
- Testing
- Probiotics
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Probi AB
Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder
A Pilot Study on Efficacy of Digital Therapeutic NDTx-02 for Executive Function in Children and Adolescents With ADHD or ASD
The purpose of this study is to explore the preliminary safety and effectiveness of the digital therapeutic device 'NDTx-02' in supporting improvements of executive function in children and adolescents diagnosed with…
- Trial name
- NCT07242625
- Testing
- NDTx-02 + TAU, TAU
- Where
- 3 sites in South Korea
- Volunteers
- 48 people
- Sponsor
- Neudive Inc.
Attention Deficit Hyperactivity Disorder (ADHD)
Superiority of Omega-3 Versus Placebo on the Improvement of ADHD in Children
This study aims to evaluate the efficacy of an Omega-3 Fatty Acid Supplement on improving the Attention Deficit Hyperactivity Disorder (ADHD) clinical symptoms.
- Trial name
- ECOMEGA (NCT02248948)
- Testing
- Omega-3 Fatty Acids, Medium Chain Triglycerides
- Where
- Spain
- Volunteers
- 231 people
- Sponsor
- Laboratorios Ordesa
Healthy
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Modified-Release Formulations of AZD1446 After Oral Single and Repeated Doses
The purpose of this study is to assess safety, tolerability and pharmacokinetics of AZD1446 in young and elderly healthy Japanese volunteers.
- Trial name
- NCT01199315
- Testing
- AZD1446
- Where
- Japan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Attention Deficit Hyperactivity Disorder
A Trial to Assess the Pharmacokinetics, Safety, and Tolerability of Centanafadine in Pediatric Subjects With Attention-deficit/Hyperactivity Disorder
This trial will evaluate the pharmacokinetics, safety, and tolerability of centanafadine in pediatric subjects with ADHD.
- Trial name
- NCT04398225
- Testing
- Centanafadine
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
ADHD
CTx-1301 Comparative Bioavailability Study
The primary purpose of this study is to compare the bioavailability of CTx-1301 (dexmethylphenidate) to the registered listed drug, Focalin XR and to evaluate dose proportionality of CTx-1301.
- Trial name
- NCT04138498
- Testing
- Dexmethylphenidate 5 Mg Oral Capsule, Extended Release, Dexmethylphenidate 6.25 mg Tablet, Dexmethylphenidate 40 Mg Oral Capsule, Extended Release
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Cingulate Therapeutics
ADHD
PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD
This is a randomized, double-blind, parallel group, placebo-controlled, dose optimized, phase 3 study to evaluate the safety and efficacy of PRC-063 in the treatment of ADHD in pediatric subjects between 6 to 12 years of age.
- Trial name
- NCT03172481
- Testing
- PRC-063 oral capsules
- Where
- 6 sites in United States
- Volunteers
- 156 people
- Sponsor
- Purdue Pharma, Canada
ADHD
A Novel, Non-pharmacological, Intervention for the Management of ADHD in Adolescents
This is a 2-month study in which eligible ADHD adolescents will be provided with personalized VIZO Glasses
- Trial name
- NCT05835336
- Testing
- VIZO Glasses
- Where
- Israel
- Volunteers
- 32 people
- Sponsor
- VIZO Specs Ltd
ADHD
Treatment Compliance in Children and Adolescents on ADHD Medication
The primary research objective of this observational study is to evaluate treatment compliance over one year in children and adolescents who are newly initiated on medication approved for the treatment of ADHD in a routine…
- Trial name
- COMPLY (NCT00540826)
- Testing
- Atomoxetine, stimulants (any approved ADHD medication)
- Where
- Germany
- Volunteers
- 518 people
- Sponsor
- Eli Lilly and Company
ADHD
Placebo-Controlled Comparison of Two Different Brands of Modified-Release Oral Dosage Forms Regarding Safety and Efficacy in Children With Attention Deficit Hyperactivity Disorder (ADHD) Aged 6 - 14
Currently two different brands of modified-release formulations are providing 50% immediate release beads/pellets and 50% extended release beads/pellets, resulting in a rapid onset and dual peak concentrations of plasma…
- Trial name
- NCT00254878
- Testing
- Methylphenidate hydrochloride
- Where
- Germany
- Volunteers
- 130 people
- Sponsor
- Novartis